TRU Pharm 2020 Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
| Term | Definition |
| Tensilon | (Edrophonium) Mode of action: Indirect acting cholinergic A primary use: Diagnosing neuromuscular weakness due to Myasthenia Gravis Timings: Very quick half life (10 min); very rapid onset |
| Methacholine | Mode of action: Direct acting cholinergic (same structure of acetylcholine) A Primary use: Used diagnostically in Pulmonary Function to rule out Asthma |
| Cocaine | Mode of action: Indirect acting adrenergic A primary use: Local vasoconstrictor and local anesthetic; rarely used for this purpose |
| Ventolin | (Salbutamol) Mode of action: Direct acting B2 agonist A primary use: A rescue Bronchodilator Dosages: MDI = 100ug, Nebulue = 2.5-5.0mg Timings: Onest = 5-15 min, Peak effect = 30-60 min, Duration 4-6 hours |
| Bricanyl | (Terbutaline) Mode of action: Direct acting B2 agonist A primuary use: Bronchodilator (not used that much) Only comes in a dry powdered form (e.g. not able to give through a ventilator circuit) |
| Serevent | (Salmeterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy for Asthma and COPD Timings: Lasts 12 hours; slower onset (15-20 mins) |
| Oxeze | (Formoterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy for COPD and Asthma. Possible reliever of acute symptoms as well due to is fast onset. Timings: Quick onset (5 mins); 12 hour duration |
| Onbrez | (Indacaterol) Mode of action: Direct acting beta 2 agonist A primary use: Maintenance therapy in COPD and Asthma Timings: 24 hr duration |
| Atrovent | (Ipratropium Bromide) Mode of action: Direct acting Muscarinic Antagonist (E.g. Anti-cholinergic or Anti-muscainic) A primary effect: Act as a short acting bronchodilator (reliever) Timings: Onset 15-20 min; Peak effect 1-2 hours; Duration 4-6 hours |
| Combivent | Mode of action: SABA and SAMA A combination of Ventolin and Atrovent A primary use: Reliever for acute bronchoconstriction |
| Spiriva | (Tiotropium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (maintenance) Timings: Long acting agent (24 hours); once daily dosing |
| Seebri | (Glycopyrronium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent (24 hours); once daily dosing |
| Tudorza | (Aclidinium) Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent with high enough dosing (12-24 hours); once or twice daily dosing |
| Incruse | (Umeclidinium): Mode of action: Direct acting competitive muscarinic antagonist A primary effect: Bronchodilation (Maintenance) Timings: Long acting agent (24 hours); once daily dosing |
| Anoro | Combination LAMA + LABA Vilanterol + Umeclidinium |
| Ultibro | Combination LAMA + LABA Indacaterol + Glycopyrronium |
| Inspiolto | Combination LAMA + LABA Olodaterol + Tiotropium |
| Duaklir | Combination LAMA + LABA Formoterol + Aclidinium |
| Caffeine | Mode of action: Methylxanthine; increases central chemoreceptor sensitivity to CO2 A primary use: Treating apnea of prematurity |
| Theophylline | Mode of action: Methylxanthine; can inhibit Phospho-diesterase-enzyme and adenosine which increases cAMP A primary use: Bronchodilation Side effects: Low therapeutic index |
| Aminophylline | Mode of action: Methylxanthine; can inhibit Phospho-diesterase-enzyme and adenosine which increases cAMP A primary use: Bronchodilation Side effects: Easier to titrate dose compared to Theophylline as less potent |
| Cortef | (Hydrocortisone) Mode of action: Acts on intracellular corticosteroid receptors. A primary use: Systemic steroid. Used as a replacement in those with decreased normal production as it is similar to cortisol, |
| Prednisone | Mode of action: Acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Used in acute respiratory (asthma) exacerbations and to suppress auto-immune diseases. Very common. |
| Decadron | (Dexamethasone) Mode of action: Acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Potent systemic steroid. Reserved for cases where quicker effects are needed. |
| Flovent | (Fluticasone Propionate) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Very common; used for maintenance of Asthma symptoms |
| Pulmicort | (Budesonide) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Maintenance of Asthma symptoms; can be nebilized. |
| Arnuity | (Fluticasone Furoate) Mode of action: Inhaled agent that acts on intracellular corticosteroid receptors. Uses many methods to produce anti-inflammatory effects A primary use: Maintenance of Asthma symptoms. Once daily dosing. |
| Alvesco | (Ciclesonide) Mode of action: Inhaled agent. Is a Prodrug and is inactive until comes in contact with respiratory epithelium. Once in contact, is converted to effective corticosteroid A primary use: Maintenance of Asthma symptoms. |
| Accolate | (Zafirlukast) Mode of action: Leukotriene receptor antagonists; competitive antagonist A primary use: And add-on therapy to reducing inflammation in Asthma |
| Singulair | (Montelukast) Mode of action: Leukotriene receptor antagonists; competitive antagonist A primary use: And add-on therapy to reducing inflammation in Asthma |
| Xolair | (Omalizumab) Mode of action: Anti-IgE; binds to free circulating IgE which prevents it binding to mast cells A primary use: Add on therapy to reduce inflammation in Asthma |
| Nucala | (Mepolizumab) Mode of action: Anti-interleukin 5; binds to free circulating IL-5 which prevent its binding to receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
| Cinqair | (Reslizumab) Mode of action: Anti-interleukin 5; binds to free circulating IL-5 which prevent its binding to receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
| Fasenra | (Benralizumab) Mode of action: Anti-interleukin 5; competitively binds to IL-5 receptors A primary use: Add-on therapy to reduce inflammation in Asthma |
| Daxas | (Roflumilast) Mode of action: Phosphodiesterase 4 inhibitor; blocks action of phosphodiesterase 4 which increases cAMP in some inflammatory cells A primary use: Add-on therapy in reducing symptoms in those with severe COPD |
| Advair | Serevent & Fluticason Combination LABA+ICS |
| Symbicort | Formoterol & Budesonide Combination LABA+ICS |
| Zenhale | Fomoterol & Mometasone Combination LABA+ICS |
| Breo | Vilanterol & Fluticasone Furoate Combination LABA+ICS |
| Trelegy | Breo + Umeclidinium Combination of 3 agents: LABA + ICS + LAMA |
| Mucomyst | (N-Acetylcysteine) Mode of action: Breaks up di-sulphide bonds that link mucus together A primary use: As a mucolytic. Is used for other things as well (tylenol overdose treatment) Other: Often causes bronchoconstriction and irritation; bad odor |
| Pulmozyme | (Dornase-Alfa): Mode of action: Breaks up DNA present in mucus A primary use: A mucolytic for those suffering from cystic fibrosis |
| Hypertonic Saline: | Mode of action: Draws in surrounding fluid due to its hypertonic nature A primary use: As an expectorant (drawing more fluid means increasing amount of mucus) |
| Dextromethorphan: | Mode of action: Suppresses medulla cough center A primary use: Commonly found compound in anti-cough/cold medications |
| Codeine: | Mode of action: Suppresses medulla cough center A primary use: Commonly found compound in anti-cough/cold medications |
| Robinul | (Glycopyrrolate): Mode of action: Anti-Muscarinic A primary use: Used to dry out secretions due to its anti-muscarinic effects |
| Scopolamine: | Mode of action: Anti-Muscarinic A primary use: Used to dry out secretions due to its anti-muscarinic effects |
| Esbriets | (Pirfenidone): Mode of action: Slows down fibroblast growth A primary use: Used in idiopathic pulmonary fibrosis to slow progression of fibrosis |
| OFEV | (Nintedanib): Mode of action: Slows down fibroblast growth A primary use: Used in idiopathic pulmonary fibrosis to slow progression of fibrosi |
Created by:
WyattN
Popular Respiratory Therapy sets